Susan Desmond-Hellmann, chancellor of UCSF, has a big idea to change the drug approval process at the Food and Drug Administration (FDA). The current process is binary, allowing for only a yes or no from the reviewer for drug approval. Desmond-Hellmann suggests that a variable approval process, that can change status as greater evidence comes in over time, will encourage more innovative products and even investment funding, based on product confidence.
